Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed / Refractory B-precursor Acute Lymphoblastic Leukemia

Pediatric Leukemia

The primary objectives of this study are to evaluate the safety and efficacy of KTE-C19 in pediatric and adolescent participants with relapsed / refractory (r / r) B-precursor acute lymphoblastic leukemia (ALL).
Pediatric Leukemia
I/II
Kitko, Carrie
NCT02625480
VICCPED15143

An Expanded Access Study of the Feasibility of Using the CliniMACS® Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients

Multiple Cancer Types

Hematologic, Leukemia, Lymphoma, Pediatric Leukemia, Pediatric Lymphoma, Pediatric Supportive Care, Pediatrics, Supportive Care
N/A
Kitko, Carrie
NCT01200017
VICCPED1619

A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies

Sickle Cell

Sickle Cell
N/A
Kassim, Adetola
NCT01850108
VICCNCBMT12108

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients with Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

This phase I / II trial studies the side effects of fludarabine phosphate, cyclophosphamide and total-body irradiation followed by donor bone marrow transplant and cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus in treating patients with primary immunodeficiency disorders or noncancerous inherited disorders. Giving low doses of chemotherapy and total-body irradiation before a bone marrow transplant helps prepare the patient’s body to accept the incoming donor’s bone marrow and decrease the risk that the patient's immune system will reject the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can attack the body's normal cells called graft versus host disease. Giving cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus after the transplant may help decrease this from happening.
Not Available
N/A
Connelly, James
NCT00358657
VICCNCPED1414

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed / Refractory Indolent Non-Hodgkin Lymphoma

Lymphoma

This study will enroll approximately 160 adult subjects who have relapsed or refractory (r / r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is made from the subjects own white blood cells which are genetically modified and grown to fight cancer. An objective response rate of 70% is targeted.
Lymphoma
II
Oluwole, Olalekan
NCT03105336
VICCBMT1844

Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed / Refractory Diffuse Large B Cell Lymphoma

Lymphoma

The purpose of this study is to evaluate whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed / refractory diffuse large B-cell lymphoma (DLBCL).
Lymphoma
III
Oluwole, Olalekan
NCT03391466
VICCBMT17102

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: